mRESVIA’s FDA approval paves the way for mRNA vaccines across multiple indications
Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has received US Food and Drug Administration (FDA) approval for use in adults ages 60 years and older, the first time that an mRNA vaccine has been approved for a disease other than Covid-19. This …